Regenerative medicine—which involves regrowing damaged or dysfunctional cells, tissues, and organs, in order to treat and cure human disease—holds great promise. Discoveries in stem cell research and tissue engineering as well as advances in regulatory and industry support have brought regenerative medicine treatments closer than ever to the clinic. Two areas showing particular potential are diabetes and vascular disease. Whether acquired or congenital, diabetes afflicts millions of people worldwide and presents a tremendous burden both in terms of physical deterioration and loss of economic capacity. Current treatments rely mainly on lifetime injections of exogenous hormones and palliative treatments with pharmaceuticals, neither of which can address the lack of properly functioning beta cells in the pancreas. Similarly, vascular diseases are among the leading causes of mortality and morbidity. The ability to generate new, clinical-grade vascular tissue is critical to the long-term treatment of complications arising from ischemic injury, stroke, aneurisms, retinopathy, and other acute and chronic vascular conditions; significant progress has been made in using stem cell sources to produce this tissue. But what is needed to get such potentially transformative treatments over the finish line?
During this webinar, the speakers will:
- Provide an overview of regenerative medicine
- Explain how close treatments for diseases such as diabetes and vascular disease are to clinical approval
- Answer viewer questions live during the broadcast.
This webinar will last for approximately 60 minutes.